title: The breast implant controversy.
abstract: The breast implant issue is a "bad news/good news" story. For many women with implants, the controversy has caused a fair degree of anxiety which may or may not be resolved as further information becomes available. It has also taken its toll on Dow Corning. Whole lines of medical products have been eliminated or are being phase out. The development of new medical applications has been terminated. As a consequence, employees have lost their jobs. What the effect will be on the biomedical industry as a whole remains to be seen (11). While silicones have been an important component in various medical devices, it is likely that other materials can be used as replacements. However, suppliers of non-silicone materials are also reevaluating their role in this market. For example, Du Pont, the nation's largest chemical company, has determined that the unpredictable and excessive costs of doing business with manufacturers of implantable medical devices no longer justifies the unrestricted sale of standard raw materials into this industry. Other companies are quietly following suit. On the up side, it is possible that the research being driven by this controversy will result in a greater understanding of the immunologic implications of xenobiotics, of the importance of nonbiased observations, of the need for ready access to valid data sets, and of the opportunity for valid scientific information to guide legal decisions. Only time will tell.
authors.affiliation: Dow Corning Corporation, Midland, Michigan 48686-0994.
authors.forename: R R
authors.initials: RR
authors.lastname: Cook
authors.forename: M C
authors.initials: MC
authors.lastname: Harrison
authors.forename: R R
authors.initials: RR
authors.lastname: LeVier
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D007221:Industry; D007603:Jurisprudence; D016462:Mammaplasty / Q000639:trends; D019736:Prostheses and Implants / Q000009:adverse effects; D012106:Research; D012449:Safety